



ALABAMA MEDICAID AGENCY

PREFERRED DRUG LIST (PDL) REFERENCE TOOL

Table of Contents

<u>Antigout Agents</u>	Page 2
<u>Antihistamine</u>	Page 2
<u>Anti-infective Agents</u>	Page 2
<u>Behavioral Health</u>	Page 7
<u>Cardiovascular Health</u>	Page 10
<u>Diabetic Agents</u>	Page 14
<u>Disease-Modifying Antirheumatic Drugs/TIMs</u>	Page 16
<u>Eye, Ear, Nose, and Throat (EENT) Preparations</u>	Page 17
<u>Gastrointestinal Agents</u>	Page 18
<u>Genitourinary Agents</u>	Page 19
<u>Hormones and Synthetic Substitutes</u>	Page 19
<u>Hereditary Angioedema Agents</u>	Page 20
<u>Immunomodulatory Agents used to treat MS</u>	Page 20
<u>Pain Management & Autonomic Agents</u>	Page 21
<u>Allergy and Respiratory Agents</u>	Page 23
<u>Skin & Mucous Membrane Agents</u>	Page 24
<u>Women's Health</u>	Page 27

Note: This PDL reference tool is to aid a prescriber with generic availability and preferred product status.

Note: A "substitution allowed" prescriber signature on a prescription should not require a PA to be obtained if a generic agent is available, if applicable.

Footnotes:

*Denotes a generic available in at least one dosage form or strength (generic will be on corresponding line where applicable)

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/ Biologics/ DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

Antigout Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antigout Agents		
none	allopurinol	Aloprim*
	colchicine tablets	Colcrys*
		colchicine capsules
		Gloperba
		Krystexxa
		Mitigare*
	febuxostat	Uloric*
	probenecid	
	probenecid-colchicine	
Antihistamines		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
First Generation Antihistamines		
none		Ryclora
	clemastine (tablet)	Clemastine (generic syrup)
	diphenhydramine	
Anti-Infective Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Adamantanes		
none	amantadine	none
	rimantadine	
Amebicides		
none	paromomycin	none
Aminoglycosides		
Bethkis*		tobramycin inhalation solution (generic Bethkis)
Kitabis*		tobramycin inhalation solution (generic Kitabis)
		Arikayce
	tobramycin inhalation solution (generic TOBI)	TOBI*
		TOBI Podhaler
		Zemdri
	amikacin	
	gentamicin	
	neomycin	
	streptomycin	
	tobramycin	
Anthelmintics		
none	praziquantel	Biltricide*
		Egaten
		Emverm
	ivermectin	Stromectol*
	albendazole	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antifungals		
none		Abelcet
	amphotericin B liposome	AmBisome*
	flucytosine	Ancobon*
		Brexafemme
	caspofungin	Cancidas*
		Cresemba
	fluconazole	Diflucan*
		Eraxis
	micafungin	Mycamine*
	posaconazole	Noxafil*
		Rezzayo
	itraconazole	Sporanox*
		Tolsura
	voriconazole	Vfend*
		Vivjoa
	amphotericin B	
	griseofulvin	
	ketoconazole	
	nystatin	
	terbinafine	
Antileprosy Agents		
none	dapsone	none
Antimalarials		
none		Coartem
		Krintafel
	atovaquone and proguanil	Malarone*
		Sovuna
	chloroquine	
	hydroxychloroquine	
	mefloquine	
	primaquine	
	pyrimethamine	
	quinine	
Antiprotozoals, Cryptosporidiosis		
none	nitazoxanide	none
Antiprotozoals, Miscellaneous		
none	none	Lampit
Antiprotozoals, Nitroimidazole-derivative		
none		Likmez
		Solosec
	benznidazole	
	metronidazole	
	tinidazole	
Antiprotozoals, <i>Pneumocystis jirovecii</i> Pneumonia		
none	atovaquone	Mepron*
	pentamidine	NebuPent*
	pentamidine	Pentam 300*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antituberculosis Agents		
none	ethambutol	
	rifabutin	Mycobutin*
		Priftin
	rifampin	Rifadin*
		Sirturo
		Trecator
	cycloserine	
	isoniazid	
	pretomanid	
	pyrazinamide	
Cephalosporins		
none		Avycaz
	cefotaxime	Claforan*
		Fetroja
	ceftazidime	Tazicef*
		Teflaro
		Zerbaxa
	cefaclor	
	cefadroxil	
	cefazolin	
	cefdinir	
	cefepime	
	cefixime	
	cefpodoxime	
	cefprozil	
	ceftriaxone	
	cefuroxime	
	cephalexin	
Chloramphenicol		
none	chloramphenicol	none
CMV Antivirals		
none	none	Livtency
		Prevymis
Coronavirus (COVID-19)		
Paxlovid	none	none
Endonuclease Inhibitors †The preferred status of this product is contingent upon statewide influenza epidemiology status as reported by the CDC		
Xofluza†	none	none
HCV Antivirals		
Mavyret ^{CC}		
Zepatier ^{CC}		
	sofosbuvir-velpatasvir ^{CC}	Epclusa*
	ledipasvir-sofosbuvir ^{CC}	Harvoni*
		Sovaldi
		Vosevi
HDV Antivirals		
		Hepcludex**
Interferons		
none	none	Pegasys

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Macrolides		
none		Dificid
	erythromycin ethylsuccinate	E.E.S.*
	erythromycin ethylsuccinate	EryPed*
	erythromycin lactobionate	Erythrocin Lactobionate*
		Erythrocin Stearate
	azithromycin	Zithromax*
	clarithromycin	
	clarithromycin ER	
	erythromycin base	
Miscellaneous Antibacterials		
none		Aemcolo DR
	clindamycin	Cleocin*
	colistimethate	Coly-Mycin M*
		Dalvance
	vancomycin	Firvanq*
		Kimyrsa
	lincomycin	Lincocin*
		Orbactiv
	bismuth/metronid/tetracycline	Pylera*
		Sivextro
	vancomycin	Vancocin*
		Vibativ
		Xenleta
		Xifaxan
	linezolid	Zyvox*
	daptomycin	
	polymyxin B sulfate	
Miscellaneous Antivirals		
none	foscarnet	Foscavir*
Miscellaneous β-Lactams		
none	aztreonam	Azactam*
		Cayston
	cefotetan	Cefotan*
	imipenem and cilastatin	Primaxin*
		Recarbrio
		Vabomere
	ertapenem	
	cefoxitin	
	meropenem	
Neuraminidase Inhibitors		
†The preferred status of this product is contingent upon statewide influenza epidemiology status as reported by the CDC		
Relenza†		
		Rapivab
	oseltamivir†	Tamiflu*
Nucleosides and Nucleotides		
(Note: Viread is a non-PDL agent available with no PA for hep B treatment)		
none	entecavir	Baraclude*
	adefovir	
	valganciclovir	Valcyte*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	valacyclovir	Valtrex*
		Veklury
		Vemlidy
	ribavirin	
	acyclovir	
	cidofovir	
	famciclovir	
	ganciclovir	
Penicillins		
none	amoxicillin and clavulanate	Augmentin*
		Bicillin C-R
		Bicillin L-A
	penicillin G	Pfizerpen*
	ampicillin and sulbactam	Unasyn*
	piperacillin and tazobactam	Zosyn*
	amoxicillin	
	ampicillin	
	dicloxacillin	
	nafcillin	
	oxacillin	
	penicillin VK	
Quinolones		
none		Baxdela
	ciprofloxacin	Cipro*
	ciprofloxacin ER	
	levofloxacin	
	moxifloxacin	
	ofloxacin	
Sulfonamides		
none	sulfasalazine	Azulfidine*
	sulfamethoxazole and trimethoprim	Bactrim*
	sulfamethoxazole and trimethoprim	Bactrim DS*
	sulfadiazine	
Tetracyclines		
none	doxycycline	Doryx*
		Minocin
	doxycycline	Morgidox*
		Nuzyra
	tigecycline	Tygacil*
		Xerava
	demeclocycline	
	minocycline	
	tetracycline	
Urinary Anti-infectives		
none	nitrofurantoin and nitrofurantoin macrocrystals	Macrobid*
	methenamine, methylene blue, phenyl salicylate, sodium phosphate, and hyoscyamine	Uribel*
		Urelle
	fosfomycin	
	nitrofurantoin macrocrystals	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	methenamine	
	methenamine, sodium phosphate, methylene blue and hyoscyamine	
	trimethoprim	
Behavioral Health		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Alzheimer's Agents		
none		Adlarity
	donepezil	Aricept*
	rivastigmine	Exelon*
		Kisunla
		Legembi
		Legembi Iqlik
	memantine	Namenda*
	memantine	Namenda XR*
	memantine and donepezil	Namzaric*
		Zunveyl DR
	galantamine	
Antidepressants		
none	clomipramine	Anafranil*
		Aplenzin
		Auvelity ER
	citalopram	Celexa*
	duloxetine	Cymbalta*
		desvenlafaxine ER (generic Khedezla)
		Drizalma
	venlafaxine	Effexor XR*
		Emsam
		Fetzima
	bupropion	Forfivo XL*
	escitalopram	Lexapro*
		Marplan
	phenelzine	Nardil*
	desipramine	Norpramin*
	nortriptyline	Pamelor*
	paroxetine	Paxil*
	paroxetine	Paxil CR*
		Pexeva
	desvenlafaxine succinate	Pristiq*
	fluoxetine	Prozac*
		Raldesy
	mirtazapine	Remeron*
		sertraline capsules (generic)
	doxepin	Silenor*
		Spravato
		Trintellix
	vilazodone	Viibryd*
	bupropion	Wellbutrin SR*
	bupropion	Wellbutrin XL*
	sertraline	Zoloft*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Zurzuvae
	amitriptyline	
	amitriptyline and chlordiazepoxide	
	amoxapine	
	fluvoxamine	
	imipramine	
	maprotiline	
	nefazodone	
	protriptyline	
	tranylcypromine	
	trazodone	
	trimipramine	
Anxiolytics, Sedatives, and Hypnotics: Barbiturates		
none		Amytal Sodium
		Sezaby
	pentobarbital	
	phenobarbital	
Anxiolytics, Sedatives, and Hypnotics: Benzodiazepines		
none	diazepam rectal kit	
		Alprazolam Intensol
	lorazepam	Ativan*
	triazolam	Halcion*
	clonazepam	Klonopin*
		Loreev XR
	temazepam	Restoril*
	clorazepate	Tranxene*
	alprazolam	Xanax*
	alprazolam ER	Xanax XR*
	chlordiazepoxide	
	diazepam	
	estazolam	
	flurazepam	
	midazolam	
	oxazepam	
Anxiolytics, Sedatives, and Hypnotics: Miscellaneous Agents		
none	zolpidem	Ambien*
	zolpidem	Ambien CR*
		Edluar
	tasimelteon	Hetlioz*
	eszopiclone	Lunesta*
	dexmedetomidine	Precedex*
	ramelteon	Rozerem*
	hydroxyzine	Vistaril*
	buspirone	
	droperidol	
	meprobamate	
	zaleplon	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Cerebral Stimulants/ Agents Used for ADHD (Short- and Intermediate-Acting)		
Ritalin*	methylphenidate	
	amphetamine-dextroamphetamine	Adderall*
	amphetamine	Evekeo*
	dexmethylphenidate IR	Focalin*
	methylphenidate	Methylin*
	dextroamphetamine	ProCentra*
	dextroamphetamine	Zenzedi*
	methamphetamine	
Cerebral Stimulants/ Agents Used for ADHD (Long-Acting)		
Adderall XR*	amphetamine-dextroamphetamine ER	
Concerta*	methylphenidate ER	
Daytrana*		methylphenidate transdermal patch (generic)
Focalin XR*	dexmethylphenidate ER	
Vyvanse Capsules*		lisdexamfetamine dimesylate (generic capsules)
		Adzenys XR-ODT
	methylphenidate	Aptensio XR*
		Azstarys
		Cotempla XR
	dextroamphetamine	Dexedrine*
		Dyanavel XR
	guanfacine ER	Intuniv*
		Jornay PM
	dextroamphetamine-amphetamine ER	Mydayis ER*
		Qelbree ER
		Quillichew ER
		Quillivant XR
	methylphenidate	Relexxi ER*
	methylphenidate	Ritalin LA*
	atomoxetine	Strattera*
	lisdexamfetamine dimesylate (generic chewable)	Vyvanse Chewable Tablets*
		Xelstrym
	clonidine ER	
Orexin Receptor Antagonists		
none	none	Belsomra
		Dayvigo
		Quviviq
Wakefulness Promoting Agents		
none	armodafinil	Nuvigil*
	modafinil	Provigil*
		Sunosi
		Wakix
		Xyrem
		Xywav

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

Cardiovascular Health		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
ACE Inhibitors		
none	quinapril	Accupril*
	quinapril and HCTZ	Accuretic*
	enalapril	Epaned*
	benazepril	Lotensin*
	benazepril and HCTZ	Lotensin HCT*
		Qbrelis
	lisinopril and HCTZ	Zestoretic*
	lisinopril	Zestril*
	captopril	
	captopril and HCTZ	
	enalapril and HCTZ	
	fosinopril	
	fosinopril and HCTZ	
	moexipril	
	perindopril	
	ramipril	
	trandolapril	
	trandolapril and verapamil	
Alpha-Adrenergic Blocking Agents		
none	doxazosin	Cardura*
		Cardura XL
		Tezruy
	prazosin	
	terazosin	
Angiotensin II Receptor Antagonists		
none		Arbli
	candesartan	Atacand*
	candesartan and HCTZ	Atacand HCT*
	irbesartan and HCTZ	Avalide*
	irbesartan	Avapro*
	olmesartan	Benicar*
	olmesartan and HCTZ	Benicar HCT*
	losartan	Cozaar*
	valsartan	Diovan*
	valsartan and HCTZ	Diovan HCT*
		Edarbi
		Edarbyclor
	losartan and HCTZ	Hyzaar*
	telmisartan	Micardis*
	telmisartan and HCTZ	Micardis HCT*
	olmesartan, amlodipine, and HCTZ	Tribenzor*
	telmisartan and amlodipine	
Angiotensin II Receptor Antagonists/Neprilysin Inhibitors		
none	sacubitril and valsartan	Entresto*
Antiarrhythmic Agents		
none		Multaq
	disopyramide	Norpace*
		Norpace CR
	amiodarone	Pacerone*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	dofetilide	Tikosyn*
	flecainide	
	mexiletine	
	propafenone	
	quinidine	
Oral Anticoagulants		
Eliquis		
Pradaxa (pellets)		
Xarelto*	rivaroxaban	
	warfarin	
	dabigatran	Pradaxa* (capsule)
		Savaysa
Beta-Adrenergic Blocking Agents		
Hemangeol ^{CC}		
	sotalol	Betapace*
	sotalol	Betapace AF*
	nebivolol	Bystolic*
	propranolol	Inderal LA*
		Inderal XL
		InnoPran XL
		Kapspargo
	metoprolol	Lopressor*
		Sotylize
	atenolol and chlorthalidone	Tenoretic*
	atenolol	Tenormin*
	metoprolol	Toprol XL*
	acebutolol	
	betaxolol	
	bisoprolol	
	bisoprolol and HCTZ	
	carvedilol	
	labetalol	
	metoprolol and HCTZ	
	nadolol	
	nadolol and bendroflumethiazide	
	pindolol	
	timolol	
Calcium-Channel Blocking Agents		
none	amlodipine and olmesartan	Azor*
	diltiazem	Cardizem*
	diltiazem	Cardizem CD*
	diltiazem	Cardizem LA*
	amlodipine and valsartan	Exforge*
	amlodipine, valsartan and HCTZ	Exforge HCT*
		Katerzia
	amlodipine and benazepril	Lotrel*
	diltiazem	Matzim LA*
		Norliqva
	amlodipine	Norvasc*
		Nymalize
	nifedipine	Procardia XL*
	nisoldipine	Sular ER*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	diltiazem	Tiazac*
	verapamil	Verelan PM*
	felodipine	
	isradipine	
	nicardipine	
	nimodipine	
	nisoldipine	
Cardiotonic Agents		
none	ivabradine	Corlanor*
	digoxin	Lanoxin*
		Lanoxin Pediatric
Central Alpha-Agonists		
none		Nexiclon XR
	clonidine patches	
	clonidine	
	guanfacine	
	methyldopa	
cGMP Synthesis Agents		
none	none	Verquvo
Direct Vasodilators		
none	isosorbide dinitrate-hydralazine	BiDil*
	hydralazine	
	minoxidil	
Endothelin Receptor Antagonists		
none	none	Tryvio
Diuretics		
none		Furoscix
		Hemiclor
	furosemide	Lasix*
		Thalitone
	amiloride	
	amiloride and HCTZ	
	bumetanide	
	ethacrynic acid	
	chlorthalidone	
	chlorothiazide	
	hydrochlorothiazide (HCTZ)	
	indapamide	
	metolazone	
	torsemide	
	triamterene	
	triamterene and HCTZ	
Mineralocorticoid (Aldosterone) Receptor Antagonists		
none	spironolactone	Aldactone*
	spironolactone	Carospir*
	eplerenone	Inspra*
		Kerendia
	spironolactone and HCTZ	
Miscellaneous Cardiac Drugs		
none		Aspruzo
		Attruby

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Camzyos
		Vyndamax
		Vyndagel
	ranolazine	
Nitrates and Nitrites		
Nitro-Bid*	nitroglycerin	
Nitrostat*	nitroglycerin	
		GoNitro
	isosorbide dinitrate	Isordil*
	nitroglycerin	Nitro-Dur*
	nitroglycerin	Nitrolingual*
	isosorbide mononitrate	
Nonsteroidal Anti-inflammatory Cardiovascular Drugs		
none	none	Lodoco
Platelet-aggregation Inhibitors		
none	ticagrelor	Brilinta*
	prasugrel	Effient*
	clopidogrel	Plavix*
	aspirin and dipyridamole	
	cilostazol	
	dipyridamole	
Renin Inhibitors		
none	aliskiren	Tekturna*
Sodium-glucose (SGLT) Cotransporter Inhibitors		
none	none	Inpefa
Vasopressin Antagonists		
none	tolvaptan	Jynarque*
	tolvaptan	Samsca*
ACL Inhibitors		
none	none	Nexletol
		Nexlizet
ANGPTL3 Inhibitors		
none	none	Evkeeza
Bile Acid Sequestrants		
none	colestipol	Colestid*
	cholestyramine	Questran*
	cholestyramine	Questran Light*
	colesevelam	Welchol*
Cholesterol Absorption Inhibitors		
none	ezetimibe	Zetia*
Fibric Acid Derivatives		
none	fenofibrate	Lipofen*
	gemfibrozil	Lopid*
	fenofibrate, nanocrystallized	TriCor*
	fenofibric acid	Trilipix*
	fenofibrate, micronized	
HMG-CoA Reductase Inhibitors		
none		Altoprev
		Atorvaliq
	amlodipine/atorvastatin	Caduet*

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Ezallor
		Flolipid
	fluvastatin	Lescol XL*
	atorvastatin	Lipitor*
	pitavastatin	Livalo*
	simvastatin/ezetimibe	Vytorin*
	simvastatin	Zocor*
		Zypitamag
	lovastatin	
	pravastatin	
	rosuvastatin	
Miscellaneous Antilipemic Agents		
none		Leqvio
		Tryngolza
	niacin	
Microsomal Triglyceride Transfer Protein (MTP) Inhibitors		
none	none	Juxtapid
Omega-3-mediated Antilipemics		
none	icosapent ethyl	none
	omega-3 acid ethyl esters	
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors		
none	none	Praluent
		Repatha
Diabetic Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Alpha-Glucosidase Inhibitors		
none	acarbose	none
	miglitol	
Amylinomimetics		
none	none	SymlinPen
Antidiabetic Agents, Miscellaneous		
none	mifepristone	Korlym*
		Tzield
Biguanides		
none		Glumetza*
		metformin ER (generic Glumetza ER)
	metformin	
Dipeptidyl Peptidase-4 (DPP-4) Inhibitors		
Janumet		
Janumet XR		
Januvia		
Jentadueto		
Jentadueto XR		
Kazano*		alogliptin-metformin (generic)
Oseni*		alogliptin-pioglitazone (generic)
Tradjenta		
	alogliptin	Nesina*

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	sitagliptin	Zituvio*
	saxagliptin	
	saxagliptin-metformin	Zituvimet*
	saxagliptin-metformin XR	Zituvimet XR*
Incretin Mimetics ^Zepbound is preferred with clinical criteria for its Obstructive Sleep Apnea (OSA) with obesity indication. Zepbound is non-covered for weight reduction without OSA. #Wegovy is available via PA for its cardiovascular and metabolic dysfunction-associated steatohepatitis (MASH) indications. Wegovy is non-covered for weight reduction.		
Byetta ^{cc}		exenatide (generic)
Mounjaro ^{cc}		
Ozempic ^{cc}		
Rybelsus ^{cc}		
Trulicity ^{cc}		
Victoza ^{cc}		liraglutide (generic)
Wegovy ^{cc #}		
Zepbound ^{cc ^}		
Meglitinides		
none	nateglinide	none
	repaglinide	
Insulins		
Fiasp		
Humalog*	insulin lispro	
Humalog Mix		
Humulin R (U-500)		
Lantus*		insulin glargine
Novolog Mix		
		Admelog
		Afrezza
		Apidra
		Apidra Solostar
		Basaglar
		Kirsty
		Levemir
		Lyumjev
		Merilog
		Myxredlin
	insulin aspart	Novolog*
		Rezvoglar
		Semglee
		Soliqua
		Tresiba
	insulin glargine max solostar	Toujeo Max Solostar*
	insulin glargine solostar	Toujeo Solostar*
		Xultophy
	Humulin N	
	Humulin R	
	Humulin 70/30	
	insulin lispro protamine 72/25 mix pen	

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	Novolin N	
	Novolin R	
	Novolin 70/30	
Sodium-glucose Co-transporter 2 Inhibitors		
Farxiga*	none	dapagliflozin (generic)
Jardiance		
Synjardy		
Synjardy XR		
Xigduo XR*		dapagliflozin/metformin ER (generic)
		Glyxambi
		Invokamet
		Invokamet XR
		Invokana
		Qtern
		Segluromet
		Steglatro
		Steglujan
		Trijardy XR
Sulfonylureas		
none	glimepiride	
	glipizide	Glucotrol XL*
	glyburide	
	glipizide and metformin	
	glyburide and metformin	
Thiazolidinediones		
none	pioglitazone and metformin	Actoplus Met*
	pioglitazone	Actos*
	pioglitazone and glimepiride	Duetact*
Disease-Modifying Antirheumatic Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Therapeutics Immunomodulators (TIMs)/ Disease-Modifying Antirheumatic Agents (DMARDs)		
Enbrel ^{CC,TIM}		
Humira ^{CC,TIM}		
Otezla ^{CC,TIM}		
Rinvoq ^{CC,TIM}		
Starjemza ^{CC,TIM}		
Yesintek ^{CC,TIM}		
		Abrilada ^{TIM}
		Actemra ^{TIM}
		Amjevita ^{TIM}
	leflunomide ^{TIM}	Arava ^{*TIM}
		Avsola ^{TIM}
		Benlysta ^{TIM}
		Cimzia ^{TIM}
		Cosentyx ^{TIM}
		Cyltezo ^{TIM}

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Entyvio ^{TIM}
		Hadlima ^{TIM}
		Hulio ^{TIM}
		Hyrimoz ^{TIM}
		Idacio ^{TIM}
		Inflectra ^{TIM}
		Kevzara ^{TIM}
		Kineret ^{TIM}
		Lupkynis ^{TIM}
		Olumiant ^{TIM}
		Orencia ^{TIM}
	infliximab ^{TIM}	Remicade ^{*TIM}
		Renflexis ^{TIM}
		Saphnelo ^{TIM}
		Simlandi ^{TIM}
		Simponi ^{TIM}
		Simponi Aria ^{TIM}
		Stelara ^{TIM}
		Taltz ^{TIM}
		Tofidence ^{TIM}
		Tyenne ^{TIM}
		Xeljanz ^{TIM}
		Xeljanz XR ^{TIM}
		Yuflyma ^{TIM}
		Yusimry ^{TIM}
		Zymfentra ^{TIM}

**Eye, Ear, Nose, and Throat
(EENT) Preparations**

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antiallergic Agents		
Bepreve*		bepotastine ophthalmic solution (generic)
		Alomide
		Zerviate
	azelastine	
	cromolyn	
	epinastine	
	olopatadine	
Antibacterials		
Besivance		
Cipro HC		
Zylet		
		AzaSite
	ciprofloxacin	Ciloxan*
		Cortisporin-TC
	neomycin, polymyxin B and dexamethasone	Maxitrol*
	ofloxacin	Ocuflox*
	ciprofloxacin and fluocinolone	Otovel*
	tobramycin and dexamethasone	TobraDex*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		TobraDex ST
	tobramycin	Tobrex*
	moxifloxacin	Vigamox*
	gatifloxacin	
	bacitracin	
	bacitracin and polymyxin B	
	ciprofloxacin and dexamethasone	
	erythromycin base	
	gentamicin	
	levofloxacin	
	neomycin, bacitracin and polymyxin B	
	neomycin, bacitracin, polymyxin B and hydrocortisone	
	neomycin, polymyxin B and gramicidin	
	neomycin, polymyxin B and hydrocortisone	
	ofloxacin	
	polymyxin B and trimethoprim	
	sulfacetamide	
	sulfacetamide and prednisolone	
Intranasal Corticosteroids		
Dymista*	azelastine/fluticasone	
Omnaris		
Zetonna		
		Beconase AQ
		QNASL
		QNASL Children
		Sinuva
		Xhance
	mometasone nasal spray	
	flunisolide	
	fluticasone	
Vasoconstrictors		
none	phenylephrine	none
Gastrointestinal Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
5-HT₃ Receptor Antagonists		
none		Anzemet
		Sancuso
		Sustol
	granisetron	
	ondansetron	
	palonosetron	
Antiemetic Antihistamines		
none	meclizine	Antivert*
		Bonjesta
	doxylamine/pyridoxine	Diclegis*
	trimethobenzamide	Tigan*
	dimenhydrinate	
	meclizine	
	prochlorperazine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Neurokinin-1 Receptor Antagonists		
none		Akynzeo
		Aponvie
		Cinvanti
	aprepitant/fosaprepitant	Emend*
Miscellaneous Antiemetics		
none		Barhemsys
	dronabinol	Marinol*
	scopolamine	Transderm-Scop*
Antiulcer Agents and Acid Suppressants		
none	dexlansoprazole	Dexilant*
		Konvomep
	esomeprazole magnesium	Nexium*
		omeprazole/sodium bicarbonate (generic)
	lansoprazole	Prevacid*
	omeprazole	Prilosec*
	pantoprazole	Protonix*
		Talicia
		Voquenza
		Voquenza Dual
		Voquenza Triple
	lansoprazole/amoxicillin/ clarithromycin	
	rabeprazole	
Genitourinary Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Genitourinary Smooth Muscle Relaxants: Antimuscarinics		
Oxytrol		
	tolterodine	Detrol*
	tolterodine	Detrol LA*
	fesoterodine	Toviaz*
	solifenacin	Vesicare*
	darifenacin	
	flavoxate	
	oxybutynin	
	trospium	
Genitourinary Smooth Muscle Relaxants: Beta-3 Adrenergic Agonists		
Myrbetriq*	none	mirabegron (generic)
		Gemtesa
Hormones and Synthetic Substitutes		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Androgens		
none		Androderm
	testosterone	AndroGel*
		Aveed

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	testosterone cypionate	Depo-Testosterone*
		Jatenzo
		Natesto
	testosterone	Testim*
		Testopel
		Tlando
	testosterone	Vogelxo*
		Xyosted
	danazol	
	methyltestosterone	
	oxandrolone	
	testosterone enanthate	
	Growth Hormone Agents	
Genotropin ^{CC}	none	
Omnitrope ^{CC}		
Skytrofa ^{CC}		
Sogroya ^{CC}		
Zomacton ^{CC}		
		Humatrope
		Ngenla
		Norditropin
		Nutropin
		Saizen
		Serostim
Agents for the Treatment of Hereditary Angioedema		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Hereditary Angioedema (HAE) Agents		
none		Berinert
		Cinryze
	icatibant	Firazyr*
		Haegarda
		Kalbitor
		Orladeyo
		Ruconest
	icatibant	Sajazir*
		Takhzyro
Immunomodulatory Agents for Multiple Sclerosis (MS)		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Multiple Sclerosis Agents		
Avonex		
Betaseron		
Copaxone*		glatiramer (generic)
Rebif		
Tysabri		
	teriflunomide	Aubagio*
		Bafiertam

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Briumvi
		Extavia
	fingolimod	Gilenya*
		Kesimpta
		Lemtrada
		Mavenclad
		Mayzent
		Ocrevus
		Ocrevus Zunovo
		Plegridy
		Ponvory
		Tascenso ODT
	dimethyl fumarate	Tecfidera*
		Vumerity
		Zeposia (follow TIMs criteria for UC indication)
Pain Management & Autonomic Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Analgesics and Antipyretics, Miscellaneous		
Journavx ^{CC}	none	none
Centrally Acting Skeletal Muscle Relaxants		
none	cyclobenzaprine	Amrix*
		carisoprodol (generic)
	cyclobenzaprine	Fexmid*
	chlorzoxazone	Lorzone*
	methocarbamol	Robaxin*
	metaxalone	
		Soma*
	tizanidine	Zanaflex*
Calcitonin Gene-related Peptide (CGRP) Antagonists		
Aimovig ^{CC}	none	
Ajovy ^{CC}		
Qulipta ^{CC}		
Ubrelvy ^{CC}		
		Emgality
		Nurtec ODT
		Vyepti
		Zavzpret
Direct-Acting Skeletal Muscle Relaxants		
none	dantrolene	Dantrium*
	dantrolene	Revonto*
		Ryanodex
GABA-derivative Skeletal Muscle Relaxants		
none	baclofen	Fleqsuvy*
	baclofen	Gablofen*

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Lioresal Intrathecal
		Lyvispah
Miscellaneous Skeletal Muscle Relaxants		
none	orphenadrine/aspirin/caffeine	Norgesic Forte*
	orphenadrine	
Opiate Agonists		
none	benzhydrocodone/acetaminophen	Apadaz*
	meperidine	Demerol*
	hydromorphone	Dilaudid*
		Dsuvia
		Duramorph
	fentanyl	Fentora* (discontinued 9/30/2024)
		Infumorph
		methadone (generic)
		Methadose*
		Nucynta
		Olinvyk
	oxycodone/acetaminophen	Percocet*
		Prolate
	oxycodone	Roxicodone*
		Seglantis
	remifentanyl	Ultiva*
	alfentanyl	
	codeine	
	codeine/acetaminophen	
	codeine/butalbital/acetaminophen/ caffeine	
	codeine/butalbital/aspirin/caffeine	
	hydrocodone/acetaminophen	
	hydrocodone/ibuprofen	
	ibuprofen/oxycodone	
	levorphanol	
	morphine	
	opium/belladonna	
	oxycodone/aspirin	
	oxymorphone	
	sufentanyl	
	tramadol	
	tramadol/acetaminophen	
Opiate Partial Agonists		
Brixadi ^{CC}		
Sublocade ^{CC}		
		buprenorphine/naloxone film (generic)
		Belbuca
		buprenorphine (generic)
		Butrans*
		Suboxone*
		Zubsolv
	buprenorphine/naloxone tablets ^{CC}	
	butorphanol	
	nalbuphine	

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	pentazocine/naloxone	
Selective Serotonin Agonists		
none	frovatriptan	Frova*
	sumatriptan	Imitrex*
	rizatriptan	Maxalt*
	rizatriptan	Maxalt MLT*
	eletriptan	Relpax*
		Reyvow
		Tosymra
		Zembrace
	zolmitriptan	Zomig*
	zolmitriptan	Zomig ZMT*
	almotriptan	
	naratriptan	
	sumatriptan and naproxen	
Allergy and Respiratory Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Asthma and Allergy Monoclonal Antibodies		
Fasenra ^{CC,TIM}	none	Cinqair ^{TIM}
Tezspire ^{CC,TIM}		Nucala ^{TIM}
Xolair ^{CC,TIM}		
Inhaled Antimuscarinics		
Atrovent HFA		
Incruse Ellipta		
Spiriva Handihaler*		tiotropium (generic)
Spiriva Respimat		
		Tudorza Pressair
		Yupelri
	ipratropium bromide	
Inhaled Mast-Cell Stabilizers		
none	cromolyn sodium	none
Leukotriene Modifiers		
none	zafirlukast	Accolate*
	montelukast	Singulair*
		zileuton ER (generic)
		Zyflo
Respiratory Corticosteroids		
Advair Diskus*		fluticasone/salmeterol (Diskus)
Advair HFA*		fluticasone/salmeterol (HFA)
Arnuity Ellipta		
Asmanex HFA		
Asmanex Twisthaler		
Breo Ellipta*		fluticasone/vilanterol (generic)
Dulera		
Pulmicort Flexhaler		
QVAR Redihaler		
Symbicort*		budesonide/formoterol (generic)
	fluticasone/salmeterol	AirDuo Respiclick*
		Airsupra

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Alvesco
		Breztri Aerosphere
	budesonide	Pulmicort Respules*
		Trelegy Ellipta
	fluticasone	
Respiratory Beta-Adrenergic Agonists		
Anoro Ellipta*		umeclidinium-vilanterol (generic)
Bevespi		
ProAir Respiclick		
Serevent Diskus		
Stiolto Respimat		
Striverdi Respimat		
Ventolin HFA*	albuterol HFA	
	arformoterol	Brovana*
		Combivent Respimat
		Duaklir Pressair
	formoterol	Perforomist*
	levalbuterol HFA	Xopenex HFA*
	levalbuterol inhalation solution	
	albuterol	
	albuterol/ipratropium	
	metaproterenol	
	terbutaline	
Respiratory Smooth Muscle Relaxants		
none		Theo-24
	aminophylline	
	theophylline	
Skin & Mucous Membrane Agents		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Antibacterials		
none	mupirocin	Centany*
	clindamycin (vaginal only)	Cleocin*
	clindamycin (vaginal only)	Clindesse*
		Neo-Synalar
		Nuessa
		Sulfamylon
	metronidazole	Vandazole*
		Xaciat
		Xepi
	gentamicin	
	neomycin and polymyxin B	
Antifungals		
none	ciclopirox	Ciclodan*
		Ertaczo
		Gynazole-1
		Jublia
	ciclopirox	Loprox*
	luliconazole	Luzu*
	naftifine	Naftin*
		Oravig

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	oxiconazole	Oxistat*
	miconazole/zinc/petrolatum	Vusion*
	clotrimazole	
	clotrimazole and betamethasone	
	econazole	
	ketoconazole	
	miconazole	
	nystatin	
	nystatin and triamcinolone	
	sulconazole	
	tavaborole	
	terconazole	
Corticosteroids		
none		
	hydrocortisone	Anusol-HC*
	fluticasone	Beser*
		Bryhali
	clobetasol	Clodan*
	hydrocortisone	Cortenema*
		Cortifoam
	fluocinolone	Derma-Smooth/FS*
	betamethasone dipropionate and propylene glycol	Diprolene*
	triamcinolone	Kenalog*
	halobetasol	Lexette*
	hydrocortisone butyrate	Locoid*
	hydrocortisone butyrate	Locoid lipocream*
	triamcinolone	Oralene*
		Pandel
		ProctoFoam-HC
	fluocinolone	Synalar*
		Texacort
	desoximetasone	Topicort*
	clobetasol	Tovet*
	halobetasol	Ultravate*
	fluocinonide	Vanos*
	alclometasone	
	amcinonide	
	betamethasone dipropionate	
	betamethasone valerate	
	clocortolone	
	halcinonide	
	desonide	
	diflorasone	
	flurandrenolide	
	hydrocortisone	
	mometasone	
	prednicarbate	
Antipruritics and Local Anesthetics		
none	lidocaine topical patch	Lidoderm*
	doxepin	Prudoxin*
	doxepin	Zonalon*

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

^{cc}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		ZTLido
	lidocaine	
	lidocaine and prilocaine	
Antivirals		
none	penciclovir	Denavir*
		Xerese
		Ycanth
		Zovirax (cream)
	acyclovir	Zovirax (ointment)*
Cell Stimulants and Proliferants		
none	none	none
Immunomodulatory Agents		
Adbry ^{CC,TIM}		
Dupixent ^{CC,TIM}		
Ebglyss ^{CC,TIM}		
		pimecrolimus (generic)
Nemluvio ^{CC,TIM}		
		Bimzelx ^{TIM}
		Hyftor
		Ilumya ^{TIM}
		Siliq ^{TIM}
		Skyrizi ^{TIM}
		Spevigo ^{TIM}
		Tremfya ^{TIM}
	tacrolimus	
Janus Kinase Inhibitors		
none		Cibinqo ^{TIM}
		Opzelura
		Sotyktu ^{TIM}
Keratolytic Agents		
none	podofilox	Condylox*
		Duobrii
		Podocon-25
		Veregen
	acitretin	
	tazarotene	
Miscellaneous Anti-inflammatory Agents		
none	none	none
Miscellaneous Local Anti-infectives		
none	silver sulfadiazine	Silvadene*
	silver sulfadiazine	SSD*
	silver nitrate	
Miscellaneous Skin and Mucous Membrane Agents		
none		Filsuvez
	calcitriol	
Phosphodiesterase-4 Inhibitors		
Eucrisa ^{CC}		
		Zoryve
Scabicides and Pediculicides		
none		Crotan
	spinosad	Natroba*

*Denotes a generic available in at least one dosage form or strength

Effective 07/01/2026

**Will be reviewed at a future time when eligible

^{CC}Denotes agent is preferred with clinical criteria in place.

^{TIM} Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
	crotamiton	Pruradik*
	ivermectin	
	malathion	
	permethrin	
Women's Health		
NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
Estrogens/ Treatments for Menopausal Symptoms		
Premarin (cream and tablets only)		conjugated estrogens tablets (generic)
Prempro		
	estradiol and norethindrone	Activella*
		Angeliq
		Bijuva
	estradiol	Climara*
		Climara Pro
		Combipatch
	estradiol valerate	Delestrogen*
		Depo-Estradiol
	estradiol	Divigel*
		Duavee
		Elestrin
	estradiol	Estrace*
		Estring
		Evamist
		Femring
	ethinyl estradiol and norethindrone	Jinteli*
		Menest
		Menostar
	estradiol and norethindrone	Mimvey*
		Prefest
		Premarin (injection)
		Premphase
	estradiol	Vagifem*
		Veozah
	estradiol	Vivelle-Dot*
Prenatal Vitamins		
Concept DHA*	prenatal vitamins, iron, folic acid, omega-3 fatty acids	
Concept OB*	prenatal vitamins, iron, folic acid	
Nestabs		
Nestabs DHA		
Thrivite Rx		
Tricare		
Vinate II		
Vitafof FE+ softgel		
Vitafof Prenatal w/iron Gummies		
Vitafof-OB		
Vitafof-OB+DHA		
Vitafof-One softgel		
Vitafof Ultra softgel		

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026

NO PA REQUIRED	NO PA REQUIRED	PA REQUIRED
Preferred Brand	Preferred Generic	Non-Preferred Brand or PA Generic
		Citranatal 90 DHA
		Citranatal Assure
		Citranatal B-Calm
		Citranatal Harmony
		Enbrace HR
		Natal PNV
		Nestabs One
	prenatal vitamins, iron, folic acid	OB Complete*
	prenatal vitamins, iron, folic acid, DHA	OB Complete Caplet*
		OB Complete One
		OB Complete Petite
		OB-Complete Premier
		OB Complete with DHA
		Prenate
		Prenate AM
		Prenate DHA
		Prenate Elite
		Prenate Enhance
		Prenate Essential
		Prenate Mini
		Prenate Pixie
		Prenate Restore
		Prenate Star
		Primacare
		Provida OB
		Select-OB
		Select-OB+DHA
		Tristart DHA
		Vinate DHA RF
		VP-CH Plus
		Zatean-PN Plus

*Denotes a generic available in at least one dosage form or strength

**Will be reviewed at a future time when eligible

ccDenotes agent is preferred with clinical criteria in place.

TIM Denotes agent managed through the Targeted Immunomodulators (TIMs)/Biologics/DMARDs criteria. Agents are preferred across PDL classes for all FDA-approved indications.

Effective 07/01/2026